Updated just now · Live
Stock analysis, price data, and AI-powered insights for Abcellera Biologics Inc (ABCL).
Abcellera Biologics Inc operates in the Life Sciences Tools & Services sector. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for ABCL.
How to read insider trading filings
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). ABCL Stock Intelligence Report. [stoxpulse.com/stocks/abcl]
Disclaimer: The information on this page about Abcellera Biologics Inc (ABCL) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for Abcellera Biologics Inc.
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
No price data available.
No earnings data available.
AbCellera To Disclose Interim Results From Phase 1...
1d ago
AbCellera to Highlight Phase 1 Clinical Data for A...
1d ago
StoxPulse AI results for ABCL: Pulse Score 43/100. Primary sentiment trends from 4 news sources and 20 SEC filings indicate a neutral outlook.
Market Cap
$1.19B
P/E Ratio
—
EPS
$-0.19
Volume
0
Avg Volume
—
Open
—
Prev. Close
—
Day Range
—
50-Day Avg
—
200-Day Avg
—
52W High
—
52W Low
—
AbCellera To Disclose Interim Results From Phase 1 Portion Of Its Study Of ABCL635, Including Observed Safety Profile, Pharmacokinetic, And Pharmacodynamic Target Engagement Data, During Q1 Earnings Call On May 11
AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call
Is Jones Trading’s New Coverage of AbCellera (ABCL) Reframing Its Clinical-Stage Platform Narrative?
AbCellera Biologics (ABCL) Committed to Leverage Differentiated Technology for Drug Discovery